Our Company
Company Objectives:
- Develop drugs to a stage of a profitable value inflection point
- Co-develop drugs starting in as late clinical stage as possible
Technology Strategy:
- Preferably already in human trials
- Robust animal data to treat cancer or viral infection
- Strong IP filings and/or issued patents
Strong Financial Position:
- Over $100M in cash, cash equivalents and marketable securities; burn < $7M yearly
- Stock currently trading below cash value
- No pending registration statements
- No debt
- No unusual financing